Figure 1
From: Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
Treatment and blood sampling schedules. MOC31PE was administered as an i.v. infusion every second week, either alone or the day after the first administration of cyclosporin (CsA). CsA was given either i.v. injection or orally, once daily for 5 consecutive days, every second week. Blood sampling for pharmacokinetic studies was done before MOC31PE infusion and 3, 6, 12, 24 and 48 h after infusion. Blood samples for measuring anti-MOC31PE antibodies were drawn before MOC31PE infusion and every second week before new MOC31PE infusions.
